| Literature DB >> 23826160 |
Der-Chong Tsai1, Shih-Jen Chen, Chin-Chou Huang, Pesus Chou, Chia-Min Chung, Po-Hsun Huang, Shing-Jong Lin, Jaw-Wen Chen, Tseng-Ji Chen, Hsin-Bang Leu, Wan-Leong Chan.
Abstract
OBJECTIVES: The epidemiology of idiopathic central serous chorioretinopathy (CSCR) is not well understood in an Asian population. The present study aimed to investigate the incidence and risk factors for corticosteroid-unrelated CSCR using Taiwan's National Health Insurance Research Database. METHODS ANDEntities:
Mesh:
Year: 2013 PMID: 23826160 PMCID: PMC3691239 DOI: 10.1371/journal.pone.0066858
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Annual Incidence of Idiopathic Central Serous Chorioretinopathy, 2001–2006.
| Year | Incident Cases | Person-Years | Annual Incidence (‰) |
| 2001 | 113 | 614,796 | 0.18 |
| 2002 | 119 | 620,004 | 0.19 |
| 2003 | 138 | 625,904 | 0.22 |
| 2004 | 111 | 631,561 | 0.18 |
| 2005 | 148 | 635,947 | 0.23 |
| 2006 | 157 | 639,860 | 0.24 |
| Average | 131 | 628,012 | 0.21 |
Age- and Sex-Specific Annual Incidence of Idiopathic Central Serous Chorioretinopathy, 2001–2006.
| Mean Annual Incidence (‰) | ||||
| Age, years | Total | Male | Female |
|
|
| 0.12 | 0.10 | 0.14 | 0.223 |
|
| 0.21 | 0.18 | 0.23 | 0.254 |
|
| 0.20 | 0.20 | 0.19 | 0.739 |
|
| 0.30 | 0.44 | 0.17 | <0.001 |
|
| 0.26 | 0.40 | 0.11 | <0.001 |
|
| 0.20 | 0.33 | 0.08 | <0.001 |
|
| 0.22 | 0.30 | 0.13 | <0.001 |
|
| 0.21 | 0.21 | 0.20 | 0.869 |
|
| 0.12 | 0.13 | 0.11 | 0.587 |
|
| 0.21 | 0.27 | 0.15 | <0.001 |
Comparisons between Female and Male Patients with Idiopathic Central Serous Chorioretinopathy by Age.
|
|
|
| |||||||
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
| Hypertension | 1 (0.7) | 2 (1.6) | 0.602 | 3 (3.4) | 31 (11.0) |
| 15 (25.4) | 26 (27.7) | 0.761 |
| Diabetes mellitus | 1 (0.7) | 0 | 1.000 | 2 (2.3) | 9 (3.2) | 1.000 | 7 (11.9) | 10 (10.6) | 0.814 |
| Hyperlipidemia | 0 | 0 | - | 4 (4.5) | 26 (9.2) | 0.163 | 13 (22.0) | 13 (13.8) | 0.188 |
| Chronic kidney disease | 2 (1.4) | 1 (0.8) | 1.000 | 2 (2.3) | 9 (3.2) | 1.000 | 1 (1.7) | 4 (4.3) | 0.649 |
| Sleep apnea | 0 | 1 (0.8) | 0.469 | 0 | 1 (0.4) | 1.000 | 1 (1.7) | 0 | 0.386 |
| Gout | 1 (0.7) | 6 (4.9) | 0.054 | 2 (2.3) | 22 (7.8) | 0.067 | 5 (8.5) | 6 (6.4) | 0.750 |
| Malignancy | 2 (1.4) | 0 | 0.500 | 0 | 3 (1.1) | 1.000 | 1 (1.7) | 4 (4.3) | 0.649 |
| Autoimmune disorders* | 4 (2.9) | 6 (4.9) | 0.523 | 7 (8) | 13 (4.6) | 0.277 | 4 (6.8) | 2 (2.1) | 0.206 |
| Allergic respiratory disorders† | 16 (11.5) | 15 (12.2) | 0.864 | 9 (10.2) | 30 (10.6) | 0.921 | 13 (22.0) | 14 (14.9) | 0.259 |
| Exposure to anti-anxietydrugs | 0 | 2 (1.6) | 0.219 | 3 (3.4) | 17 (6.0) | 0.429 | 9 (15.3) | 9 (9.6) | 0.289 |
P value less than 0.05 in bold.
Characteristics of Male Cases and Controls.
| Male cases | Male controls | ||
| (n = 500) | (n = 2294) |
| |
| Age, mean years (SD) | 40.5 (9.5) | 40.4 (9.8) | 0.731 |
| Monthly income, n (%) | 0.536 | ||
| <NT$15,000 | 104 (20.8) | 506 (22.1) | |
| NT$15,000–30,000 | 203 (40.6) | 952 (41.5) | |
| NT$30,001–50,000 | 115 (23.0) | 534 (23.3) | |
| >NT$50,000 | 78 (15.6) | 302 (13.2) | |
| Place of residence, n (%) | 0.338 | ||
| Northern | 232 (46.4) | 1027 (44.8) | |
| Central | 128 (25.6) | 631 (27.5) | |
| Southern | 127 (25.4) | 600 (26.2) | |
| Eastern | 13 (2.6) | 36 (1.6) | |
| Medical history, n (%) | |||
| Hypertension | 59 (11.8) | 200 (8.7) |
|
| Diabetes mellitus | 19 (3.8) | 102 (4.4) | 0.520 |
| Hyperlipidemia | 39 (7.8) | 152 (6.6) | 0.346 |
| Chronic kidney disease | 14 (2.8) | 36 (1.6) | 0.060 |
| Sleep apnea | 2 (0.4) | 5 (0.2) | 0.616 |
| Gout | 34 (6.8) | 178 (7.8) | 0.463 |
| Malignancy | 7 (1.4) | 28 (1.2) | 0.744 |
| Autoimmune disorders | 21 (4.2) | 93 (4.1) | 0.881 |
| Allergic respiratory disorders | 59 (11.8) | 225 (9.8) | 0.182 |
| Exposure to anti-anxiety drugs | 28 (5.6) | 69 (3.0) |
|
SD, standard deviation; NT$, New Taiwan Dollar.
Including Graves’ disease, sarcoidosis, psoriasis, connective tissue disease, Reiter’s syndrome, rheumatoid arthritis, ankylosing spondylitis, thrombocytopenic purpura, ulcerative colitis, and Crohn’s disease.
Including asthma, allergic rhinitis, and sinusitis.
P value less than 0.05 in bold.
Characteristics of Female Cases and Controls.
| Female cases | Female controls | ||
| (n = 286) | (n = 1312) |
| |
| Age, mean years (SD) | 37.2 (11.8) | 37.4 (11.5) | 0.793 |
| Monthly income, n (%) | 0.884 | ||
| <NT$15,000 | 87 (30.4) | 431 (32.9) | |
| NT$15,000–30,000 | 114 (39.9) | 508 (38.7) | |
| NT$30,001–50,000 | 69 (24.1) | 301 (22.9) | |
| >NT$50,000 | 16 (5.6) | 72 (5.5) | |
| Place of residence, n (%) | 0.136 | ||
| Northern | 84 (29.4) | 370 (28.2) | |
| Central | 157 (54.9) | 782 (59.6) | |
| Southern | 39 (13.6) | 149 (11.4) | |
| Eastern | 6 (2.1) | 11 (0.8) | |
| Medical history, n (%) | |||
| Hypertension | 19 (6.6) | 93 (7.1) | 0.789 |
| Diabetes mellitus | 10 (3.5) | 53 (4.0) | 0.669 |
| Hyperlipidemia | 17 (5.9) | 54 (4.1) | 0.174 |
| Chronic kidney disease | 5 (1.7) | 20 (1.5) | 0.792 |
| Sleep apnea | 1 (0.3) | 1 (0.1) | 0.326 |
| Gout | 8 (2.8) | 19 (1.4) | 0.126 |
| Malignancy | 3 (1.0) | 21 (1.6) | 0.602 |
| Autoimmune disorders | 15 (5.2) | 78 (5.9) | 0.647 |
| Allergic respiratory disorders | 38 (13.3) | 162 (12.3) | 0.664 |
| Exposure to anti-anxiety drugs | 12 (4.2) | 59 (4.5) | 0.823 |
| Pregnancy | 10 (3.5) | 65 (5.0) | 0.291 |
SD, standard deviation; NT$, New Taiwan Dollar.
Including Graves’ disease, sarcoidosis, psoriasis, connective tissue disease, Reiter’s syndrome, rheumatoid arthritis, ankylosing spondylitis, thrombocytopenic purpura, ulcerative colitis, and Crohn’s disease.
Including asthma, allergic rhinitis, and sinusitis.
Crude and Adjusted Odds Ratios for Idiopathic Central Serous Chorioretinopathy among Male Cases and Controls.
| Crude OR | (95% CI) | Adjusted OR | (95% CI) | |
| Monthly income, n (%) | ||||
| <NT$15,000 | Reference | Reference | ||
| NT$15,000–30,000 | 1.02 | (0.80–1.30) | 1.04 | (0.82–1.33) |
| NT$30,001–50,000 | 1.03 | (0.78–1.35) | 1.05 | (0.80–1.39) |
| >NT$50,000 | 1.18 | (0.87–1.60) | 1.20 | (0.88–1.64) |
| Place of residence, n (%) | ||||
| Northern | Reference | Reference | ||
| Central | 0.93 | (0.74–1.15) | 0.94 | (0.76–1.18) |
| Southern | 0.94 | (0.76–1.17) | 0.95 | (0.76–1.18) |
| Eastern | 1.45 | (0.83–2.54) | 1.49 | (0.85–2.61) |
| Medical history, n (%) | ||||
| Hypertension |
|
| 1.27 | (0.93–1.74) |
| Diabetes mellitus | 0.87 | (0.54–1.38) | 0.73 | (0.44–1.21) |
| Hyperlipidemia | 1.16 | (0.83–1.62) | 1.12 | (0.76–1.64) |
| Chronic kidney disease | 1.58 | (0.93–2.70) | 1.62 | (0.95–2.79) |
| Sleep apnea | 1.59 | (0.40–6.41) | 1.53 | (0.38–6.19) |
| Gout | 0.88 | (0.62–1.25) | 0.78 | (0.54–1.13) |
| Malignancy | 1.10 | (0.52–2.33) | 1.06 | (0.50–2.25) |
| Autoimmune disorders | 1.05 | (0.68–1.62) | 0.99 | (0.64–1.55) |
| Allergic respiratory disorders | 1.18 | (0.90–1.55) | 1.14 | (0.87–1.51) |
| Exposure to anti-anxiety drugs |
|
|
|
|
OR, odds ratio; CI, confidence interval; NT$, New Taiwan Dollar.
Including Graves’ disease, sarcoidosis, psoriasis, connective tissue disease, Reiter’s syndrome, rheumatoid arthritis, ankylosing spondylitis, thrombocytopenic purpura, ulcerative colitis, and Crohn’s disease.
Including asthma, allergic rhinitis, and sinusitis.
P value less than 0.05 in bold.
Crude and Adjusted Odds Ratios for Idiopathic Central Serous Chorioretinopathy among Female Cases and Controls.
| Crude OR | (95% CI) | Adjusted OR | (95% CI) | |
| Monthly income, n (%) | ||||
| <NT$15,000 | Reference | Reference | ||
| NT$15,000–30,000 | 1.12 | (0.83–1.50) | 1.11 | (0.82–1.49) |
| NT$30,001–50,000 | 1.13 | (0.81–1.58) | 1.13 | (0.81–1.58) |
| >NT$50,000 | 1.15 | (0.66–1.99) | 1.13 | (0.64–1.97) |
| Place of residence, n (%) | ||||
| Northern | Reference | Reference | ||
| Central | 0.88 | (0.68–1.16) | 0.89 | (0.68–1.17) |
| Southern | 1.18 | (0.80–1.74) | 1.22 | (0.82–1.81) |
| Eastern | 1.72 | (0.73–4.08) | 1.79 | (0.75–4.31) |
| Medical history, n (%) | ||||
| Hypertension | 0.90 | (0.54–1.51) | 0.87 | (0.50–1.50) |
| Diabetes mellitus | 0.80 | (0.41–1.54) | 0.74 | (0.37–1.47) |
| Hyperlipidemia | 1.33 | (0.79–2.25) | 1.43 | (0.81–2.50) |
| Chronic kidney disease | 1.10 | (0.45–2.71) | 1.27 | (0.52–3.14) |
| Sleep apnea | 2.47 | (0.34–17.81) | 2.50 | (0.33–18.80) |
| Gout | 1.65 | (0.81–3.39) | 1.64 | (0.78–3.43) |
| Malignancy | 0.67 | (0.21–2.11) | 0.69 | (0.22–2.17) |
| Autoimmune disorders | 0.87 | (0.51–1.47) | 0.85 | (0.50–1.46) |
| Allergic respiratory disorders | 1.07 | (0.76–1.51) | 1.06 | (0.75–1.50) |
| Exposure to anti-anxiety drugs | 0.92 | (0.51–1.67) | 0.90 | (0.49–1.68) |
| Pregnancy | 0.75 | (0.40–1.42) | 0.76 | (0.40–1.44) |
OR, odds ratio; CI, confidence interval; NT$, New Taiwan Dollar.
Including Graves’ disease, sarcoidosis, psoriasis, connective tissue disease, Reiter’s syndrome, rheumatoid arthritis, ankylosing spondylitis, thrombocytopenic purpura, ulcerative colitis, and Crohn’s disease.
Including asthma, allergic rhinitis, and sinusitis.